Text: S03211 Text: S03213 Text: S03200 - S03299 Text: S Index Bills and Amendments: General Index Bill History: General Index
PAG LIN 1 1 Amend House File 619, as amended, passed, and 1 2 reprinted by the House, as follows: 1 3 #1. Page 3, by inserting after line 18 the 1 4 following: 1 5 "Sec. . NEW SECTION. 155A.4A PHARMACEUTICAL 1 6 MARKETERS PROHIBITION OF GIFTS. 1 7 1. A pharmaceutical marketer shall not offer or 1 8 provide to any practitioner, hospital, health care 1 9 facility, or health benefit plan administrator, or any 1 10 other person in this state authorized or licensed to 1 11 dispense, distribute, or purchase prescription drugs, 1 12 any gift not otherwise exempt under this section. 1 13 2. The following gifts are exempt from the 1 14 prohibition of this section: 1 15 a. Free samples of prescription drugs intended for 1 16 distribution to patients. 1 17 b. The payment of reasonable compensation and 1 18 reimbursement of expenses in connection with bona fide 1 19 clinical trials. As used in this paragraph, "clinical 1 20 trial" means an approved clinical trial conducted in 1 21 connection with a research study designed to answer 1 22 specific questions about vaccines, new therapies, or 1 23 new ways of utilizing known treatments. 1 24 c. Any gift, fee, payment, subsidy, or other 1 25 economic benefit the value of which is less than 1 26 twenty-five dollars. 1 27 d. A scholarship or other support for medical 1 28 students, residents, or fellows to attend a 1 29 significant educational, scientific, or policymaking 1 30 conference of a national, regional, or specialty 1 31 medical or other professional association if the 1 32 recipient of the scholarship or other support is 1 33 selected by the association. 1 34 3. a. Annually on or before January 1, every 1 35 pharmaceutical manufacturing company shall disclose to 1 36 the board the value, nature, and purpose of any gift, 1 37 fee, payment, subsidy, or other economic benefit 1 38 provided in connection with detailing, promotional, or 1 39 other marketing activities by the company, directly or 1 40 through its pharmaceutical marketers, to any 1 41 practitioner, hospital, nursing home, pharmacist, 1 42 health benefit plan administrator, or any other person 1 43 in this state authorized to prescribe, dispense, or 1 44 purchase prescription drugs in this state. Disclosure 1 45 shall be made on a form and in a manner prescribed by 1 46 the board and shall be made for the period beginning 1 47 July 1 and ending June 30 of the previous state fiscal 1 48 year. An initial disclosure shall be made on January 1 49 15, 2004, for the period beginning July 1, 2003, and 1 50 ending December 31, 2003. The board shall provide to 2 1 the office of the attorney general complete access to 2 2 the information required to be disclosed under this 2 3 subsection. The office of the attorney general shall 2 4 report annually on the disclosures made under this 2 5 section to the governor and the general assembly on or 2 6 before March 1. 2 7 b. Each company subject to the provisions of this 2 8 section shall also disclose to the board, on or before 2 9 October 1, 2003, and annually thereafter, the name and 2 10 address of the individual responsible for the 2 11 company's compliance with this section. 2 12 c. The board and the office of the attorney 2 13 general shall keep confidential all trade secrets as 2 14 defined in section 550.2. The disclosure form 2 15 prescribed by the board shall permit the company to 2 16 identify any information that is a trade secret. 2 17 d. The company is exempt from disclosure of any 2 18 gifts that are exempt from the prohibition pursuant to 2 19 subsection 2. 2 20 e. The attorney general may bring an action for 2 21 injunctive relief, costs, and attorney fees, and may 2 22 impose a civil penalty of not more than ten thousand 2 23 dollars per violation on a company that fails to 2 24 disclose information as required by this subsection. 2 25 Each failure to disclose constitutes a separate 2 26 violation. 2 27 4. For the purposes of this section: 2 28 a. "Pharmaceutical manufacturing company" means 2 29 any entity engaged in the production, preparation, 2 30 propagation, compounding, conversion, or processing of 2 31 prescription drugs, either directly or indirectly by 2 32 extraction from substances of natural origin, or 2 33 independently by means of chemical synthesis, or by a 2 34 combination of extraction and chemical synthesis, or 2 35 any entity engaged in the packaging, repackaging, 2 36 labeling, relabeling, or distribution of prescription 2 37 drugs. The term does not include a wholesaler or a 2 38 pharmacist licensed under this chapter. 2 39 b. "Pharmaceutical marketer" means a person who, 2 40 while employed by or under contract to represent a 2 41 pharmaceutical manufacturing company, engages in 2 42 pharmaceutical detailing, promotional activities, or 2 43 other marketing of prescription drugs in this state to 2 44 any practitioner, hospital, health care facility, 2 45 pharmacist, health benefit plan administrator, or any 2 46 other person licensed or authorized to prescribe, 2 47 dispense, or purchase prescription drugs. 2 48 "Pharmaceutical marketer" does not include a 2 49 wholesaler or a wholesale salesperson." 2 50 #2. By renumbering as necessary. 3 1 3 2 3 3 3 4 JACK HOLVECK 3 5 DICK L. DEARDEN 3 6 DR. JOE SENG 3 7 ROBERT E. DVORSKY 3 8 WALLY E. HORN 3 9 JOHN P. KIBBIE 3 10 EUGENE S. FRAISE 3 11 KEITH A. KREIMAN 3 12 AMANDA RAGAN 3 13 DENNIS H. BLACK 3 14 MATT McCOY 3 15 HERMAN C. QUIRMBACH 3 16 STEVEN H. WARNSTADT 3 17 THOMAS G. COURTNEY 3 18 ROGER STEWART 3 19 WILLIAM A. DOTZLER 3 20 JOE BOLKCOM 3 21 JACK HATCH 3 22 HF 619.305 80 3 23 pf/cf
Text: S03211 Text: S03213 Text: S03200 - S03299 Text: S Index Bills and Amendments: General Index Bill History: General Index
© 2003 Cornell College and League of Women Voters of Iowa
Comments about this site or page?
webmaster@legis.iowa.gov.
Please remember that the person listed above does not vote on bills. Direct all comments concerning legislation to State Legislators.
Last update: Tue Apr 15 02:30:38 CDT 2003
URL: /DOCS/GA/80GA/Legislation/S/03200/S03212/030414.html
jhf